<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Brjóstakrabbamein - Pertuzumab (Perjeta®)</title>
    <link>http://brjost.eplica.is</link>
    <description>Brjóstakrabbamein</description>
    <language>is-IS</language>
    <copyright>Copyright 2026 Brjóstakrabbamein</copyright>
    <lastBuildDate>Thu, 28 May 2026 23:45:09 +0000</lastBuildDate>
    <docs>http://backend.userland.com/rss</docs>
    <managingEditor>no-reply@eplica.is</managingEditor>
    <webMaster>no-reply@eplica.is</webMaster>
    <generator>Eplica CMS - www.eplica.is</generator>
    <ttl>40</ttl>
    <item>
      <title>Pertuzumab (Perjeta®)</title>
      <link>http://brjost.eplica.is/medferdir/markmedferdir/pertuzumab-perjeta-/nr/1499</link>
      <description>N/A</description>
      <pubDate>Tue, 23 Sep 2014 13:14:00 +0000</pubDate>
      <guid isPermaLink="true">http://brjost.eplica.is/medferdir/markmedferdir/pertuzumab-perjeta-/nr/1499</guid>
    </item>
  </channel>
</rss>
